The deletion of PTPN22 did not improve the in vivo anti-tumour activity of murine HER2-specific CAR-T cells [92], reflecting a lack of effect of PTPN22-deficiency on very high-affinity T cell responses [85,86]. This evidence concerns the gene PTPN22 and neoplasm.